The US Food and Drug Administration (FDA) has issued a warning letter to Novo Nordisk over failures in reporting suspected adverse side effects linked...
Novo Nordisk shares tumbled in pre-market trading on Monday after its experimental obesity drug CagriSema failed to match the weight-loss efficacy of Eli Lilly’s...